XML 12 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2025
Sep. 30, 2024
Current Assets:    
Cash and cash equivalents $ 26,410 $ 3,251,880
Inventory 15,339,253 8,268,766
Prepaid expenses 3,008,791 2,700,000
Total Current Assets 18,374,454 14,220,646
Operating lease right-of-use asset, net 922,099 246,247
Deposits 38,062 38,062
In-process research and development 92,800,000 92,800,000
Goodwill 9,346,796 9,346,796
Total Other Assets 102,184,858 102,184,858
Total Assets 121,481,411 116,651,751
Current Liabilities:    
Accounts payable 9,368,234 4,927,211
License payable 28,400,000 28,400,000
Accrued expenses 8,779,244 17,027
Accrued compensation 3,184,066 2,229,018
Operating lease liability 145,098 241,547
Total Current Liabilities 49,876,642 35,814,803
Deferred tax liability 7,242,280 6,713,800
Operating lease liability - noncurrent 786,697 21,318
Total Liabilities 57,905,619 42,549,921
Commitments and Contingencies
Stockholders’ Equity:    
Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock - $0.001 par value; 16,000,000 shares authorized; 8,760,649 and 7,247,243 shares issued and outstanding at March 31, 2025 and September 30, 2024, respectively 8,761 7,247
Additional paid-in capital 282,705,620 271,440,421
Accumulated deficit (222,054,969) (201,370,218)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity 60,659,412 70,077,450
Non-controlling interest 2,916,380 4,024,380
Total Equity 63,575,792 74,101,830
Total Liabilities and Equity $ 121,481,411 $ 116,651,751